Recently, Prophet Genomics, a medical devices company in SIP, has received the marketing approval for its domestically pioneering chromosome abnormality detection kit for diagnosing urothelial carcinomas through the National Medical Products Administration’s “Green Channel”, a special review and approval procedure designed to facilitate registration and marketing of innovative medical products.
The company, established in SIP’s BioBAY in 2018, focuses on advancing liquid biopsy technologies that can help ensure precision of tumor diagnostics.
The product, the first approved Class-III innovative medical device from East China’s Jiangsu province this year, utilizes a cutting-edge sequencing method to detect chromosomal instability in urine samples. It is designed as a non-invasive diagnostic aid for patients with suspected urothelial carcinoma requiring further clinical examination.
January 22, 2026
